Data Characteristics
Peptide drug clinical trial data primarily originates from internal databases of clinical trial institutions, public databases of regulatory bodies like the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), and academic platforms such as PubMed and ClinicalTrials.gov. Data update frequencies vary; regulatory databases typically update upon approval or changes in trial status, while academic platforms update in real-time with paper publications or trial registrations. Document structures are mainly structured tabular data, supplemented by unstructured PDF documents such as research reports, ethics approvals, and informed consent forms. Key fields include peptide sequence, target, indication, administration route, dosage, frequency, adverse event incidence, and biomarker data. Units cover common milligrams (mg), micrograms (µg), milliliters (mL), moles (mol), percentages (%), and pharmacodynamic/pharmacokinetic specific units like AUC and Cmax.
Constraints on Reference and Traceability
The uniqueness of peptide sequences and target specificity requires references to be precise down to the specific compound and mechanism of action, avoiding generalized citations. The multi-source nature and varying update frequencies of clinical trial data necessitate attention to data publication dates and versions during traceability to ensure reference timeliness. The presence of unstructured documents, such as adverse event descriptions in trial reports, poses challenges for text extraction and information integration, requiring more refined text segmentation strategies. The diversity of units for key parameters like dosage and frequency demands that the system accurately identifies and presents them in references to prevent misinterpretations due to unit confusion. Biomarker data often appears in charts or complex tables, requiring accurate parsing of chart content and valid links to original sources during referencing.
Configuration Settings
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
Chunk size | 500-800 characters | Balances information density for peptide sequences and target descriptions, preventing information overload from excessively long segments. |
Recall count | 10-15 entries | Considers the complexity and multi-dimensionality of peptide drug clinical trial data, increasing recall to cover relevant information. |
Similarity threshold | 0.75-0.85 | Ensures precision of recalled content, reducing irrelevant information, especially for peptide sequence similarity. |
Rerank result count | 3-5 entries | For pre-screening scenarios, streamlines the final presented references, focusing on the most relevant and critical information. |
maxContext | 3000-4000 token | Ensures capacity to carry detailed descriptions of peptide drugs, trial designs, and key results, supporting complete traceability. |
PARSE_FILE_TIMEOUT_SECONDS | 600 seconds | Provides sufficient parsing time for large PDF-format clinical trial reports. |
Common Pitfalls
- References lack specific drug sequences or target names, preventing direct traceability to particular peptide molecules. This happens when knowledge base segmentation fails to effectively identify and preserve these critical entity details.
- The system returns dosage or frequency units that do not match the original text, for example, incorrectly displaying "µg" as "mg." This occurs when the unit recognition module's regular expression matching rules are incomplete during unstructured text extraction.
- When a user queries specific adverse events, the system fails to cite the relevant clinical trial report sections, instead returning generalized adverse event overviews. This happens when the knowledge base index does not fully utilize the report's chapter structure information for fine-grained segmentation.
Verification Steps
- Select multiple representative peptide drug clinical trial cases. Query for key information and verify if the system's returned references include corresponding original document links and specific paragraphs.
- Verify whether the presentation of core fields such as peptide sequence, target, dosage, and administration route in the system's returned references matches the original text, especially for the accuracy of numerical values and units.
- Simulate queries involving complex information like adverse events and biomarker data. Check if references point to original document areas containing charts or detailed descriptions, and evaluate the completeness of the referenced content.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.